Methods: VERIFY Pre-Op TIMI 45 was a prospective study of 42 patients with indications for coronary angiography subsequently referred for CABG. All patients were therapeutic on clopidogrel. Platelet function was assessed with VerifyNow™ P2Y 12 Reaction Units (PRU). Chest tube output within 24-hours of CABG was stratified by PRU Ն 208, Ն 230, and Ն 275. Results reported as meanϮSD. Results: Median time from last clopidogrel dose to CABG was 4 days (range 1 to 9 days). Patients who held clopidogrel Ͻ 4 days had lower PRU than those who held for Ն 4 days (190Ϯ84 vs. 271Ϯ21 PRU; pϭ0.015). Thresholds of PRU Ն 208 or Ն 275 correlated with less bleeding but did not reach significance (pϭ0.20 and pϭ0.39). Patients with PRU Ն 230 had significantly less chest tube output than those with PRU Ͻ 230 (622Ϯ220 vs. 1028Ϯ676; pϭ0.026) (Figure) .
Background: High on-treatment platelet reactivity (HPR) has been identified as an independent risk factor for ischemic events in acute coronary syndrome (ACS) patients (pts). In TRIPLET, ACS pts undergoing percutaneous coronary intervention (PCI) were given a prasugrel (pras) loading dose (LD) with or without a prior clopidogrel (clop) LD. An analysis of HPR was included. Methods: TRIPLET was a randomized, double-blind study in ACS-PCI pts on aspirin using VerifyNow P2Y12 assay to evaluate Pras with or without prior Clop in 3 arms: (1) placebo (PBO) followed by Pras 60-mg LD (2) Clop 600-mg LD followed by Pras 30-mg LD (3) Clop 600-mg LD followed by Pras 60-mg LD. Pts undergoing PCI received Pras 10-mg once daily (qd) for 2-4 days. HPR (P2Y12 Reaction Units [PRU] Ն240) were evaluated in the pharmacodynamic population within 24 hrs following the PBO/Clop LD, immediately prior to Pras LD and at 2, 6, 24, 72 hrs following Pras LDs. Results: HPR following Clop was 58.5% in the combined Clop LD arms. No substantial difference was noted when stratified by time between the Clop and Pras LDs (Ͻ 6hrs vs Ն6 hrs). At 6 hrs in the combined Pras LD arms, HPR was 7.1%, with 0% HPR by 72 hrs. Because a high number of HPR occurred in a single site, a statistical outlier analysis was performed. When outliers were excluded, HPR occurred in 1.9% at 6 hours and in 0% by 24 hrs. Conclusions: In TRIPLET, pts with ACS intended for PCI showed a high prevalence of HPR after Clop 600-mg LD, even when measured after 6 hrs. When Pras LD was added, HPR decreased substantially by 6 hrs and was absent by 72 hrs.
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Clopidogrel Background: Clopidogrel loading dose of 600mg is used in patients undergoing PCI and those treated for acute coronary syndromes. 600mg of clopidogrel can significantly inhibit platelet inhibition within 2 hours but also improve endothelial dysfunction in stable CAD patients via a mechanism independent of platelet function. We sought to study the effect of both acute clopidogrel 600mg loading and chronic 75mg therapy on markers of NO metabolism, vasodilatory effect and antioxidant status in these patients. Methods: 58 CAD patients were recruited. In the clopidogrel naive group (36 subjects) blood was taken before and 2h after 600mg dose of clopidogrel and 75mg aspirin (ASA)who were attending for PCI for stable angina. We studied another cohort on chronic ASA and clopidogrel 75mg (22 subjects) after 2 months of therapy. All plasma samples were measured for NO metabolites (nitrite, nitrate and S-nitrosothiols), cGMP (a marker of vasodilatory effect) and antioxidant capacity of the plasma (ORAC index). Pearson correlation statistics were performed on all acute pre and post clopidogrel loading and chronic therapy to explore the relationships seen in NO metabolites. Results: 2 hours after clopidogrel 600mg dose, plasma nitrite was increased from 157. 1Ϯ82.4 to 194.2Ϯ87.64 nM (pϭ0.012) , cGMP from 214.2Ϯ124.4 to 231.5Ϯ107.8 pmol/ml(pϭ0.05) and ORAC index from 60.66Ϯ11.45 to 64.15Ϯ10.61%(pϭ0.037). Acute loading -the rise in cGMP was inversely related to the total antioxidant capacity of the plasma (ORAC index)pϽ0.0001 also the rise in nitrite with the increase in cGMP pϭ0.0043. There was a weaker correlation in the rise in nitrate as a consequence of 600mg with the rise in ORAC pϭ0.0782. After chronic clopidogrel, nitrite was increased from 157.1Ϯ82.4 to 254.3Ϯ139.4nM(pϭ0.0028), as well as cGMP from 214.2Ϯ124.4 to 276.9Ϯ72.15pmol/ml(pϭ0.05). In both acute and chronic groups RSNO (nitrosothiol) was unchanged. Conclusions: Patients receiving clopidogrel exhibit a time-proportional increase in NO bioavailability and effective vasodilation. Clopidogrel has beneficial effects on redox status 2 hours after 600mg. These results suggest non platelet -pleiotropic effects of clopidogrel in CAD patients. 
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